Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma.
Ryan P O'ConnellKevin LiawNils WellhausenChristopher A ChuckranPratik S BhojnagarwalaDevivasha BordoloiDaniel H ParkNicholas ShupinDaniel KulpCarl H JuneDavid WeinerPublished in: Journal for immunotherapy of cancer (2024)
With impressive efficacy, the CA9-targeted PMTE is a promising new therapy for advanced ccRCC, which can be effectively delivered through synDNA. The highly potent PMTE format itself is a promising new tool for future applications in the multispecific antibody space.